Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Reset all filters
01 4Liletta
02 3Mirena Product Family
03 1Mirena product family
04 6Mirena/ Kyleena/ Jaydess
05 1MirenaTM product family
Main Therapeutic Indication : Urology
Currency : USD
2020 Revenue in Millions : 1,308
2019 Revenue in Millions : 1,479
Growth (%) : -12
Main Therapeutic Indication : Urology
Currency : USD
2021 Revenue in Millions : 1,288
2020 Revenue in Millions : 1,308
Growth (%) : 8
Main Therapeutic Indication : Women's Health
Currency : USD
2022 Revenue in Millions : 1,341
2021 Revenue in Millions : 1,288
Growth (%) : 4
Main Therapeutic Indication : Women's Health
Currency : USD
2023 Revenue in Millions : 1,312
2022 Revenue in Millions : 1,341
Growth (%) : -5
Main Therapeutic Indication : Women?s Health
Currency : USD
2024 Revenue in Millions : 1,334
2023 Revenue in Millions : 1,312
Growth (%) : 2
Main Therapeutic Indication : Sexual Health
Currency : USD
2015 Revenue in Millions : 901
2014 Revenue in Millions : 1,065
Growth (%) : 18%
Main Therapeutic Indication : Sexual Health
Currency : USD
2014 Revenue in Millions : 13.90%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Sexual Health
Currency : USD
2017 Revenue in Millions : 1,396
2016 Revenue in Millions : 1,293
Growth (%) : 8
Main Therapeutic Indication : Sexual Health
Currency : USD
2016 Revenue in Millions : 1,106
2015 Revenue in Millions : 1,026
Growth (%) : 8
Main Therapeutic Indication : Sexual Health
Currency : USD
2018 Revenue in Millions : 1,292
2017 Revenue in Millions : 1,272
Growth (%) : 2%



